<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005989</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067978</org_study_id>
    <secondary_id>U01CA069912</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>982401</secondary_id>
    <nct_id>NCT00005989</nct_id>
  </id_info>
  <brief_title>R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Study of Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have&#xD;
      recurrent or metastatic non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the response rate of patients with recurrent or metastatic non-small cell lung&#xD;
           cancer when treated with tipifarnib.&#xD;
&#xD;
        -  Determine the clinical toxicities of this treatment in these patients.&#xD;
&#xD;
        -  Assess the overall survival and time to progression of this patient population when&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Evaluate the inhibition of protein farnesylation in vivo and correlate such inhibition&#xD;
           to plasma levels of tipifarnib.&#xD;
&#xD;
        -  Evaluate the occurrence of CYP450 polymorphisms and relate these to drug toxicity,&#xD;
           pharmacokinetics, and response to this treatment in this patient population.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study over 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed recurrent or metastatic non-small cell lung&#xD;
             cancer (NSCLC)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 20 mm in at least one dimension&#xD;
&#xD;
               -  Nonmeasurable is defined as any of the following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Inflammatory breast disease&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 3 times ULN (no greater than 5 times ULN in case of hepatic&#xD;
             metastases)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No other prior malignancy in past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or other adequately treated noninvasive carcinomas&#xD;
&#xD;
          -  No other concurrent severe underlying disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior biologic, gene, or immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for NSCLC except low dose cisplatin as radiosensitizer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Prior radiotherapy to less than 25% of bone marrow allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian Molina, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>April 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2004</study_first_posted>
  <last_update_submitted>August 2, 2011</last_update_submitted>
  <last_update_submitted_qc>August 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Julian R. Molina, M.D., Ph.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

